MicroRNAs as Biomarkers and Therapeutic Targets in TNBC Webinar
Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity rate due to its aggressive behavior and lack of effective targets
Join Dr Brian Adams of Harvard Medical School as he discusses how microRNAs can serve as superior therapeutic agents in the fight against triple negative breast cancer.
About the Presenter
Brian D. Adams, PhD is currently an Instructor at Harvard Medical School in the lab of Dr Frank Slack working to elucidate the role of microRNAs (miRNAs) in TNBC, to develop miR-34a as a therapeutic agent, and to establish a miRNA biomarker profile that associates with overall outcome and drug response in TNBC patients. Brian has over 9 years of experience in the fields of microRNA and cancer research.
Brian completed his graduate studies at the University of Connecticut, where he was the first to identify that miRNAs are a crucial regulator of hormone-responsiveness in breast cancer patients. He further completed his postdoctoral studies at Yale, where he investigated how miRNAs can serve as chemo-sensitizers in the context of normal hematopoietic recovery and acute myeloid leukemia.
Brian has published a number of publications related to his research, including one from Dr Phil Askenase’s group, where they showed the first example of T-cell regulation through systemic transit of exosome-like Nanovesicles delivering an inhibitory miRNA (miR-150) to target effector T cells in an antigen-specific manner. Further, he is establishing a miRNA biomarker profile associated with obesity and weight loss in a cohort of breast cancer survivors with Dr. Melinda Irwin.
- miRNAs and noncoding RNA biology
- Dysregulation of miRNAs associates with disease etiology
- miRNAs as biomarkers
- Techniques used to profile and study miRNA biology
- miRNAs as therapeutic agents and/or targets